NEW YORK (GenomeWeb News) – Bioinformatics firm Genome Compiler has raised $500,000 toward a targeted round of $5 million, the company said in a document filed with the US Securities and Exchange Commission this week.
The Northern California-based firm did not identify investors in the round or say how the proceeds will be used. In its Form D filed with the SEC, it said that the type of securities offered comprised equity and security to be acquired upon exercise of option, warrant, or other right to acquire security.
Genome Compiler did not respond to a request for comment.
In December 2012, gene synthesis firm DNA2.0 sued the company alleging patent infringement, as BioInform reported at the time. The two companies are in the discovery phase, and a trial date has not yet been set.